Pre Next

[1] SONG Na WU Shiguo XIE Xingxing QIU Xiangyu TANG Xiaohu,.Research Progress on Molecular Mechanism of TraditionalChinese Medicine Intervention on Liver Cancer and Its Pain [J]. Modern Traditional Chinese Medicine, 2021, (04): 1-6. [doi: 10.13424/j.cnki.mtcm.2021.04.001]

Copy

Research Progress on Molecular Mechanism of TraditionalChinese Medicine Intervention on Liver Cancer and Its Pain

Modern Traditional Chinese Medicine[ISSN: 1006-6977/ CN: 61-1281/TN] Volumes & Issues: 2021 04 pagination: 1-6 Column: Publication date: 2023-11-20

Article number:: 1672-0571(2021)04-0001-06

Author(s):: SONG Na¹ WU Shiguo¹ XIE Xingxing¹ QIU Xiangyu¹ TANG Xiaohu¹; 2; 1.Yunnan University of Traditional Chinese Medicine，Kunming 650500,China;
2.Yunnan Provincial Hospital of Traditional Chinese Medicine，Kunming 650021,China

Keywords:: Liver cancer; Cancer pain; Traditional Chinese medicine; Mechanism; Research progress

ZTFLH:: R285

DOI:: 10.13424/j.cnki.mtcm.2021.04.001

Code:: A

Abstract:: Liver pain is one of the most common and painful symptoms in patients with primary liver cancer. The use of traditional Chinese medicine can synergistically relieve pain，raise pain threshold，improve the mental environment of the body，and delay or reduce the occurrence of pain. From the perspective of basic research，this article summarizes the molecular mechanisms of some drugs for promoting blood circulation and removing blood stasis，warming interior，clearing heat and detoxifying，tonifying Qi and other kinds of traditional Chinese medicine in anti-cancer and pain relief，in order to provide some basis for the combination of traditional Chinese and Western medicine to enhance the analgesic effect of cancer pain and give full play to the advantages of traditional Chinese medicine in anti-cancer and pain relief.

References:

［1］赵丹,魏海梁,李京涛,等.益脾养肝方联合索拉非尼治疗中晚期肝癌34例［J］.现代中医药,2018,38(1):31-33.
［2］蔡娲,沈卫东.针灸治疗原发性肝癌疼痛的临床研究进展［J］.针灸临床杂志,2017,33(7):76-79.
［3］《癌症疼痛诊疗规范(2018年版)》编写专家委员会.癌症疼痛诊疗规范(2018年版)［J］.临床肿瘤学杂志,2018,23(10):937-944.

［4］赖雅文,丰哲.中医药治疗癌性疼痛的研究进展［J］.大众科技,2019,21(5):100-102.

［5］覃艳春,荣震,蒋锐沅,等.中药复方制剂抑制CD133~+肝癌干细胞增殖及干性转录因子的表达［J］.中国组织工程研究,2021,25(19):3016-3023.

［6］吕明月,宁微微,陈雅慧,等.抗肿瘤药物的耐药性及临床治疗对策［J］.中国现代应用药学,2019,36(13):1721-1727.

［7］GAO C,Liang J,Zhu Y,et al.Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy.Acta Pharm Sin,2019,9:843-857.

［8］Wang X,Wang N,Cheung F,et al.Chinese medicines for prevention and treatment of human hepatocellular carcinoma:current progress on pharmacological actions and mechanisms.J Integr Med,2015,13:142-164.

［9］黄帝内经·灵枢经［M］.北京：人民卫生出版社，1963.

［10］难经［M］.北京：人民卫生出版社，2013.

［11］巢元方.诸病源候论［M］.北京：人民卫生出版社，1983.

［12］张景岳.景岳全书［M］.北京：人民卫生出版社，1994.

［13］高洺杨,覃志周,韦艾凌.中医药治疗原发性肝癌疼痛的研究进展［J］.光明中医,2016,31(6):901-902.

［14］王景春,刘蔚,杨瑞玲,等.川芎多糖对人肝癌细胞HepG2增殖及凋亡的影响［J］.南京中医药大学学报,2014,30(5):461-464.

［15］Wang L,Yan Z,Wang Z,et al.The Antinociceptive Properties of the Corydalis yanhusuo Extract［J］.PLoS One,2016,11(9):1-15.

［16］张元元,邹文静,李旭,等.基于网络药理学探讨郁金治疗肝癌的分子机制［J］.海南医学院学报,2020,26(22):1729-1735，1743.

［17］周宁,戴旖旎,白旭光,等.姜黄素对肝癌细胞凋亡及TNF-ɑ、IL-1β、IL-6炎性因子影响的机制研究［J］.癌症进展,2017,15(11):1282-1285.

［18］唐渊,李晓辉.莪术提取物对肝癌细胞系HepG2的抗癌作用及机制研究［J］.国药理学通报,2007,23(6):790-794.

［19］王春宇,王睿林,艾永强,等.活血化瘀方对小鼠Hepa1-6肝癌转移和生长的作用及机制初探［J］.中药药理与临床,2019,35(6):110-116.

［20］中药学［M］.北京：中国中医药出版社，2016.

［21］林玉坤,张舒慧,李海云,等.生附子对小鼠H22肝癌皮下移植瘤模型的抗肿瘤作用研究［J］.河南大学学报(医学版),2017,36(4):235-238.

［22］王文心.干姜的化学、药理及临床应用特点分析［J］.中医临床研究,2016,8(6):146-148.

［23］de Lima RMT,dos reis AC,de Menezes AAPM,et al.Protective and therapeutic potential of ginger（Zingiber officinale) extract and［6］-gingerol in cancer:A comprehensive review［J］.Phytother Res,2018,32(10):1885-1907.?

［24］马晓茜,赵晓民.干姜水提物解热镇痛作用的实验研究［J］.山东医学高等专科学校学报,2011,33(5):327-329.?

［25］Hu CY，Wu HT，Su YC，et al.Evodiamine exerts an anti-hepatocellular carcinoma activity through a WWOX-dependent pathway［J］.Molecules,2017,22(7).

［26］Shi L,Yang F,Luo F,et al.Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis［J］.Tumour Biol,2016,37(9):12791-12803.

［27］滕光寿,刘曼玲,毛峰峰,等.小茴香挥发油的抗炎镇痛作用［J］.现代生物医学进展,2011,11(2):344-346.?

［28］盛凤,张春艳,闫玉兰,等.四逆汤对肝母细胞瘤细胞生物学行为的影响及机制［J］.山东医药,2020,60(28):10-12.

［29］唐纯明,何自力,李军.山慈菇提取物对肝癌细胞增殖及TNF-α、IL-1β、IL-6表达的影响［J］.山东医药,2020,60(8):11-14.

［30］刘晓卉,詹盛,林秀坤,等.白花蛇舌草、半枝莲及其药对配伍对人胰腺癌Panc28细胞及人肝癌Bel7402细胞葡萄糖摄取能力及乳酸水平的影响［J］.中医杂志,2020,61(10):890-895.

［31］母慧娟,母珍珍,张淑娜,等.蒲公英含药血清对人肝癌SMMC-7721细胞增殖、黏附和运动的影响［J］.中国药师,2019,22(9):1583-1586.

［32］向东,杨金玉,张程亮,等.黄芩苷治疗原发性肝癌的研究进展［J］.世界华人消化杂志,2018,26(6):378-383.

［33］刘嘉辉,孙保国,张诗军,等.基于网络药理学和分子对接的马齿苋治疗肝癌作用机制研究［J/OL］.中药材,2020(12):3017-3023［2021-03-14］.https://doi.org/10.13863/j.issn1001-4454.2020.12.032.

［34］楚小鸽,韩慧,马璐璐,等.清热解毒方对小鼠移植性肝癌抗肿瘤作用及趋化因子的影响［J］.上海中医药杂志,2017,51(1):81-87，106.

［35］郑雪莹,曹宁宁,裴帅,等.人参皂苷Rh_2抗肝癌作用机制的研究进展［J］.中国实验方剂学杂志,2019,25(20):208-213.

［36］徐颖佳,薛赢俊,陆婵娟.顺铂作用于人肝癌细胞系HepG2后对肿瘤干细胞标志物的影响［J］.国际检验医学杂志,2016,37(8):1023.

［37］赵桂芝,浦锦宝,周洁,等.白术醇提物的抗炎镇痛活性研究［J］.中国现代应用药学,2016,33(12):1507-1512.?

［38］赵桂芝,徐攀,浦锦宝,等.白术醇提物对佐剂性关节炎大鼠足跖肿胀度和炎性细胞因子的影响［J］.浙江中医药大学学报,2017,41(1):32-37.

［39］邝佩霞,卜莺莺.异甘草素抗肿瘤作用及促凋亡机制研究［J］中南医药,2015,13(8)：806-811.

［40］卢海林,李素婷,郑林鸿.补中益气汤对肝癌患者血清TNF-α、IL-8的影响［J］.中国医药指南,2010,8(32):7-9.

［41］卢新兰,卢朝辉,曹琰,等.柴胡皂甙D诱导肝癌细胞同时发生凋亡及类凋亡性细胞死亡［J］.西安交通大学学报(医学版),2020,41(6):966-971.

［42］陈盼.基于OPG/RANKL/RANK信号通路探讨桂枝附子配伍治疗RA的骨保护机制［D］.昆明：云南中医学院,2018.

［43］彭代平,汤小虎,周瑞彬.桂枝温通经脉配伍对胶原诱导性关节炎大鼠的免疫调节作用［J］.中国中西医结合杂志,2017,37(7):813-818.

［44］贾文燕,贺松其,文彬,等.鳖甲煎丸对肝癌细胞周期及Wnt/β-catenin信号通路中β-catenin、COX-2蛋白表达水平的影响［J］.中华中医药杂志,2015,(8):2964.

［45］王淑静,刘欢,赵健凯,等.氧化苦参碱对人肝癌HepG2细胞增殖及能量代谢的影响［J］.中成药,2017,39(9):1932-1935.

［46］曾普华,郜文辉,潘敏求,等.益气化瘀解毒方药对人肝癌HepG2细胞增殖和裸鼠移植瘤生长的影响［J］.现代肿瘤医学,2014,22(1):8-11.

Memo

基金项目：国家自然科学基金项目（81960835）；云南省万人计划名医专项［云卫人发（2019）1号］；云南省卫生科技计划项目（2017NS165）；云南中医药大学研究生导师团队建设项目

Last Update: 2021-08-02